Stay updated on Fenebrutinib vs Ocrelizumab in Primary Progressive MS Clinical Trial

Sign up to get notified when there's something new on the Fenebrutinib vs Ocrelizumab in Primary Progressive MS Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Fenebrutinib vs Ocrelizumab in Primary Progressive MS Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    8 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2.
    Difference
    0.0%
    Check dated 2025-05-01T06:37:23.000Z thumbnail image
  3. Check
    15 days ago
    No Change Detected
  4. Check
    22 days ago
    Change Detected
    Summary
    The page has undergone significant changes, including the removal of detailed study information regarding the efficacy and safety of fenebrutinib for treating Primary Progressive Multiple Sclerosis, while adding new identifiers and a revision number.
    Difference
    19%
    Check dated 2025-04-16T22:10:34.000Z thumbnail image
  5. Check
    29 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.14.3 to version 2.14.4.
    Difference
    0.0%
    Check dated 2025-04-09T17:01:20.000Z thumbnail image
  6. Check
    37 days ago
    Change Detected
    Summary
    The page has been updated to reflect the latest version as v2.14.3, replacing the previous version v2.14.2. The phrasing regarding the last update has also changed from 'Estimated' to a definitive statement.
    Difference
    0.1%
    Check dated 2025-04-02T01:24:48.000Z thumbnail image
  7. Check
    44 days ago
    Change Detected
    Summary
    The study on fenebrutinib for Primary Progressive Multiple Sclerosis (PPMS) has updated its participant enrollment numbers from approximately 946 to 985 and adjusted the number of study locations from 190 to 189. Additionally, the eligibility criteria for participants regarding liver disease have been clarified.
    Difference
    7%
    Check dated 2025-03-25T21:46:06.000Z thumbnail image
  8. Check
    73 days ago
    Change Detected
    Summary
    The page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.
    Difference
    0.8%
    Check dated 2025-02-25T05:00:36.000Z thumbnail image

Stay in the know with updates to Fenebrutinib vs Ocrelizumab in Primary Progressive MS Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Fenebrutinib vs Ocrelizumab in Primary Progressive MS Clinical Trial page.